Tissue Inhibitor of Metalloproteinase 3 (TIMP3) is a secreted protein that has a great utility to inhibit elevated metalloproteinase (MMP) activity in injured tissues including infarcted cardiac tissue, inflamed vessels, and joint cartilages. An imbalance between TIMP3 and active MMP levels in the local tissue area may cause worsening of disease progression. To counter balance elevated MMP levels, exogenous administration of TIMP3 appeared to be beneficial in preclinical studies. However, the current form of WT-TIMP3 molecule has a limitation to be a therapeutic candidate due to low production yield, short plasma half-life, injection site retention, and difficulty in delivery, etc.
ECM turnover is a tightly regulated process that maintains a balance between matrix metalloproteinases (MMPs) and their endogenous inhibitor Tissue Inhibitor of Metalloproteinases (TIMPs) levels. It has been suggested that blocking MMP activity either by small molecule inhibitor or TIMP molecules immediately after disease-causing insults would be beneficial for various disease modifying conditions including acute myocardial infarction, acute lung injury, osteoarthritis, and inflammation. [1] [2] [3] [4] However, small molecule MMP inhibitors have failed in a clinical heart failure trial due to intolerable side effects, particularly musculoskeletal pain syndrome, which could be due to metabolites or off-target effects. [5] [6] [7] There have been many trials of more specific inhibitors to avoid this side effect without resolution. 8 Cardiac tissues in response to ischemia induce the breakdown of ECM by elevating MMP levels, which induces ventricular wall thinning in the infarcted area eventually resulting in heart failure. 9, 10 Postischemic loss of cardiomyocytes incites inflammatory cells, mostly neutrophils, to spike MMP levels disproportionally at the infarct site. Inadequate levels of TIMP3 to counteract protease activity at infarct site results in extensive ECM remodeling, ventricular dilation, and decline in cardiac function. 11, 12 Inhibition of MMPs, specifically MMP2 and MMP9, has been shown to prevent ECM proteolysis and reduce the infarct size following myocardial injury. 13, 14 All mammalian TIMPs (TIMP1-4) consist of two domains: Nterminal and C-terminal, with the N-terminal domain, designated N-TIMP exhibiting function. Each TIMP subtype shows inhibition of a distinct subset of MMPs, with TIMP3 being the broadest MMP, ADAM, and ADAM-T inhibitor. 15 TIMP3 is the most abundant subtype in the heart, and inhibits post-MI remodeling by reducing TNFα production via TACE (TNF alpha converting enzyme) inhibition as well as by decreasing endogenous MMP activity in the infarcted area. 7, 16 These dynamic changes of upregulated MMPs and decreased TIMP3 levels in myocardial matrix following MI lead to myocardial ECM degradation contribute to cardiac dysfunction and adverse remodeling in the failing heart. 17, 18 The level of TIMP3 was significantly reduced in post-MI animals and patients with dilated cardiomyopathy. 19, 20 Thus, it is hypothesized that the exogenous administration may compensate for the loss of cardiac tissue TIMP3 after myocardial injuries.
Modification by engineering of large protein molecules is a common method to extend serum half-life. The most common modifications are fusion with albumin or Fc, which significantly extended the half-life of protein ligands, such as interferon gamma (γINF)-fused with human serum albumin. 21 PEGylation (polyethylene glycol conjugation) has a significant pharmacokinetic effect by slowing down clearance, however there seems to be some safety concerns regarding vacuolization in renal cells. 22, 23 An additional modification approach is a site-specific glycosylation of protein molecules that improves pharmacokinetic (PK) property by increasing stability due to reduced protease sensitivity with bulky glycol moiety, which may reduce potential immunogenicity as well. 24, 25 The serum half-life and in vivo bioactivity of glycosylated recombinant human erythropoietin (rHuEPO or darbepoetin alfa), which is used to treat anemia, was improved 3-fold upon glycosylation of two additional sites (5-N- 
| Gelatin zymography
Zymography is a conventional method for detecting MMP activity.
To confirm MMP inhibition in gelatin zymography we used purified human MMP2 or MMP9 enzyme. After running the zymogram with human MMP2, the gel lanes were cut and incubated with engineered (Thermo Fisher Scientific) with or without TIMP3 molecules. The following day, gels were stained with SimplyBlue Safestain (Thermo Fisher Scientific). MMP activity was quantified using ImageJ software.
| Pharmacokinetic analysis in rats
Pharmacokinetics of TIMP3 (3 mg/kg, intravenous injection) was measured in normal male Sprague Dawley rats according to the IACUC approved protocol. TIMP3 concentrations were quantified from plasma using mass spectrometry analysis for nonfused molecules (LOQ: 10 ng/mL) and immunoassay (Gyrolab fluorescent assay, 10A7 mAb for capture and anti-HSA or Fc for detection; LOQ 100-250 ng/mL) for fused molecules. Plasma concentration data following IV administration were analyzed using either standard noncompartmental analysis or a constant IV infusion model in Phoenix version 6.4 (Pharsight, Mountain View, CA).
| Echocardiography in MI rats
Myocardial 
| Inhibition of extracellular matrix degradation
Degradation of ECM by collagenase type I (C2674 Sigma) was examined in presence of MMP inhibitors. ECM formed by 16000 HCF cultured for 7 days was used for degradation study. 100 μg of collagenase was incubated with TIMP3 or marimastat (Sigma-Aldrich) in decellularized ECM in 96-wells for 1 hour at 37°C with gentle shake. The wells were washed once with 100 μL of PBS, fixed with 4% paraformaldehyde for 15 minutes and immunostained for collagen type III.
| Fluorescent labeled TIMP3 retention in MI rat hearts
To estimate ex vivo signals of cardiac residence half-life, AF680-labeled N-TIMP3 (70 μg) or AF680-labeled F-TIMP3 (270 μg) was directly injected into the infarct area of MI rats at 1 hour post-LAD ligation before closing the chest. Hearts were harvested at desired time points within 14-day postinjection, and sliced 1 mm section on slicing block before putting into microplate, which was read in Safire multimode plate reader (Tecan) at 680 nm excitation and 702 nm emission wavelength. 
| Statistical analyses

| Zymography of TIMP3 variants
The MMP activity of gelatin digestion was detected by unstained 
| Cardiac and plasma half-life of TIMP3 variants
Exogenously delivered recombinant TIMP3 has a short plasma half-life. It was not clear if the high clearance is target-mediated respectively. As shown in Table 1 , the plasma half-life of both N-TIMP3 and TIMP3v2 was <66 minutes in the rat. We hypothesized that with a specific target mediated clearance, a continuous infusion may saturate the clearance target system. Thus, a continuous intravenous infusion of TIMP3 molecules for 6-8 hours was explored in normal rats ( Figure 3C,D) . The continuous infusion did not alter the fast clearance kinetics of TIMP3 at least in these rats although nonlinear PK pattern was observed between the low and high dose of TIMP3v2. A nonlinear PK was observed for TIMP3v2 between the low-and high-dose conditions. Both N-TIMP3 and TIMP3v2 displayed high clearance after systemic administration ( Table 2 ).
| Cardiac functional effects in MI rats
To evaluate the biological activity of TIMP3 as a heart failure target, we characterized N-TIMP3 (N-domain, 13.9 kDa), TIMP3v2 (K22S/ F34N), 5xGlyco-TIMP3 (v82), and v82 with Fc fused in the C-terminus (v82-Fc). In vitro MMP inhibitory potency was not dramatically different among modified TIMP3 molecules as these molecules potently inhibited MMP2/9 and TACE activities although they showed relatively short IV PK profiles (t 1/2 < 1 hour) except v82-Fc (Table 3A) . This is in line with the data from the pig study, in which TIMP3 inhibition of cardiac remodeling was demonstrated by reducing LVEDV and LV wall thinning in the pig MI model. 31 A highly glycosylated Fc fused TIMP3 (v82-Fc) exhibited longer half-life (15 hours) in the rat after Cardiac tissue was homogenized in RIPA buffer with PMSF. After staining and destaining, the gel was quantified using ImageJ software (lower graph). The gel is a representative of n = 3 experiments (mean ± SEM). Graphs are averages of each ImageJ scan. *P < 0.05 (vs control), **P < 0.01 (vs control)
IV delivery, which is suitable for bi-weekly injection scheme. Thus, v82-Fc was explored in the rat MI model via tail vein injection.
Unexpectedly, twice a week delivery (5 mg/kg) was not different from the untreated control group ( Figure 4D ).
| Retention of ECM binding by engineered
TIMP3 variants
TIMP3 has been known to bind to the ECM with high affinity and decreased levels associated with after myocardial infarction. To 
Concentration (nmol/L) Concentration (nmol/L)
Time (h)
Time ( (mg/heart) - As shown in Figure 4A -C), N-TIMP3 (1 mg/rat), TIMP3v2 (2 mg/rat) and TIMP3v82 (2 mg/rat) were injected directly into myocardium after 3 h post-LAD ligation in Sprague Daley rats (n = 8-10 per group). Echocardiography was performed at Day 3 and Day 7 postdose. %EF was calculated based on the equation: (LVEDV-LVESV)/LVEDV × 100 (mean ± SEM). Baseline EF at pre-MI condition was 70 ± 5%
30 seconds in the decellularized ECM condition as well as binding to the infarcted cardiac tissue area in rat hearts post-MI. IR800-labeled TIMP3v2 was incubated with ECM and showed a concentration dependent increase in retention after repeated washing with PBS ( Figure 6A ). A higher concentration induces a stronger signal. At high concentration (100 μg per well), it could bind available ECM binding sites in a saturable manner up to 60 minutes. The binding kinetics was also assessed in the infarct area of MI rat hearts ( Figure 6B ). An intravenous delivered IR800-TIMP3v2 was detected in the infarct region as early as 30 seconds, which is technically the earliest time point possible to capture in this in vivo experimental setting. However, the signal increase was plateaued up to 10 minutes after administering through tail vein injection, which may be due to high clearance of the molecule ( Figure 6B) . The plasma protein level was also detected by gel electrophoresis after blood collection (Figure 6C ). This fast localization may be due to higher levels of MMP targets in the infarct area.
| Inhibition of ECM degradation by TIMP3
In order to detect ECM degradation, the decellularized ECM produced from cardiac fibroblasts was treated with type 1 collagenase. As expected, the ECM was degraded upon collagenase treatment when collagen fibril degradation was assessed by immunostaining with type 3 collagen antibody. TIMP3 displayed a concentration-dependent inhibition of collagen fibril degradation, TIMP3 (µg/well) ** * * * F I G U R E 7 TIMP3 inhibition of collagen fibril degradation by collagenase: Collagenase type-I (100 μg/well) was incubated with acellular ECM in the presence of varying concentrations of TIMP3v2 (0, 1 μg, 3 μg, 10 μg, 30 μg, 100 μg), N-TIMP3 (300 μg) or MMP inhibitor Marimastat (100 μmol/L) for 1 hour at 37°C with gentle shake before fixing with 4% PFA. Collagen fibril degradation was assessed by immunostaining using anti-Collagen type III antibody. Scale bar = 200 μm. Graph is the average of n = 3 experiments with SEM. *P < 0.05 (vs control), **P < 0.01 (vs control), paired t test intracoronary catheter in a pig balloon occlusion model, and demonstrated that the intracoronary delivered TIMP3 can prevent adverse myocardial remodeling in ischemia-reperfusion injuries. 32 To identify a suitable TIMP3 form to improve biological property and function, we have generated multiple glycosylated forms of TIMP3 and fusion constructs. PEGylation with varying sizes of polyethylene glycols (2-20 kDa) was employed to many pharmaceutical molecules to improve the pharmacokinetic property as it prevents a rapid clearance due to its bulkiness with PEG conjugation. Indeed, PEGylated
TIMP3v2 exhibited longer plasma half-life (>28 hours) compared to other modifications (Table 1) . However, some safety concerns were raised for cellular vacuolization even though it has significant pharmacokinetic effect by slowing down clearance. 22, 23 Modification by glycosylation has been well established in large molecule ligands. For example, the PK profile of darbepoetin alfa (DA), glycosylated EPO, was dramatically improved by two additional glycosylation (5-NGlyco and 1-O-Glyco) of recombinant EPO molecule. 26 Even though TIMP3 has an endogenous glycosylation site in the C-terminus, additional glycosylation by site-specific engineering may further improve PK property by increasing stability due to reduced protease sensitivity with bulky sugar moiety, which may also reduce potential immunogenicity. 24, 25 It appeared that additional glycosylation preserved MMP inhibitory activity as well as beneficial cardiac effects in MI rats upon direct myocardial injection, but its plasma half-life extension was minimal. Interestingly, myocardial half-life after direct injection into the myocardial tissue exhibited at least 30-fold longer retention than in the plasma. A direct myocardial injection of v2 and v82 variants showed no noticeable differences in terms of cardiac function in the rat MI model evaluation (Table 3) There are limitations to the study. First, the variability of in vitro fluorescence-based MMP assays was high although the assay is more sensitive than the conventional zymography. It may be caused by aggregation of recombinant proteins, which can be improved further to reduce the variability. Second, there were relatively smaller animal numbers in the in vivo studies due to large consumption of proteins, especially infusion studies. A longer lasting TIMP3 variant will be required for future studies. Third, although the present study provided potential mechanistic insight regarding the ECM binding property and inhibition of ECM degradation, it remains to be unclear that this in vitro data can be directly translated into in vivo cardiac effects. More mechanism related studies are warranted. In conclusion, these data may suggest that an exogenous delivery of TIMP3 into the infarcted cardiac area can reduce worsening of cardiac function potentially by preventing ECM degradation in the rat heart.
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